What is the zanzalintinib setback?

The drug faced a setback in some trials, but full details have not been disclosed.

Will EXEL stock continue to grow?

It depends on the FDA decision, future trial results, and Cabometyx performance.

Exelixis Stock Surges 26.8% in 3 Months: Growth Ahead?

Exelixis (EXEL) stock rose 26.8% in three months despite a setback for zanzalintinib. Investors focus on an upcoming FDA review, phase III trials, and strong Cabometyx sales momentum.

July 9, 2026

2 min read

Source: Zacks

Key Numbers

stock gain

26.8%

period

three months

Exelixis (NASDAQ: EXEL) stock surged 26.8% over the past three months, driven by several positive catalysts despite a setback for its drug zanzalintinib. Investors are eyeing an upcoming FDA review, ongoing phase III trials, and strong momentum from Cabometyx sales.

Details

Although zanzalintinib faced a setback in some trials, the company's overall growth trajectory remains compelling. The FDA is expected to conduct a review that could impact the drug's future. Additionally, phase III trials for zanzalintinib in other indications continue to show promise.

Context

The strong stock performance comes amid volatility in the biotech sector. Part of the momentum stems from the continued success of Cabometyx, which maintains robust sales. Analyst confidence in Exelixis's ability to diversify its pipeline also supports the stock.

What It Means for Investors

The stock remains under watch as the FDA decision date approaches. Any positive development in zanzalintinib's profile or sustained growth in Cabometyx could further boost gains. However, regulatory and competitive risks should be considered.

Frequently Asked Questions

The stock rose due to an upcoming FDA review for zanzalintinib, phase III trials, and strong Cabometyx sales momentum.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.